Trial Profile
A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanic Acid Tablets 875/125 mg Every 12 Hours for the Treatment of Subjects With Complicated Skin and Skin Structure Infections
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Moxifloxacin (Primary) ; Moxifloxacin (Primary) ; Amoxicillin/clavulanic acid; Piperacillin/tazobactam
- Indications Abscess; Bacterial skin diseases; Cellulitis; Diabetic foot ulcer; Escherichia coli infections; Skin and soft tissue infections; Staphylococcal infections; Wound infections
- Focus Registrational; Therapeutic Use
- Acronyms RELIEF
- Sponsors Bayer; Bayer HealthCare
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 06 Jul 2019 Trial has been completed in Hungary, according to European Clinical Trials Database record.
- 24 Sep 2010 Results from a sub-study in patients with diabetic foot infections were presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.